MedTrace Logo

Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia

NCT03185897 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 242

Last updated 2021-10-25

No results posted yet for this study

Summary

Assess the seroprevalence of neutralizing antibodies (NAb) to AAV in adults with severe hemophilia A (coagulation factor VIII \[FVIII\] \<1%) or moderately severe to severe hemophilia B (coagulation factor IX \[FIX\] ≤2%).

Conditions

Interventions

OTHER

Non-treatment, seroprevalence

Non-treatment study examining the prevalence of preexisting immunity to adeno-associated virus (AAV)

Sponsors & Collaborators

  • Baxalta now part of Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Shire

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-14
Primary Completion
2021-03-17
Completion
2021-03-17

Countries

  • United States
  • Austria
  • France
  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03185897 on ClinicalTrials.gov